hotspot -WSS

hotspot

author：hotspot 2025-09-02 08:25:52 - browse：33647

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： CDC's new outbreak response network to include Northeastern

WSS

Chemotherapy drug shortage eases slightly but still widespread

Senate panel eyes new effort on drug shortages

CDC's new outbreak response network to include Northeastern

Microbiome research is starting to find links to chronic diseases

Senators: Long

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Alkermes shareholders re

CDC's new outbreak response network to include Northeastern

Hepatitis C has a cure — but many Americans still lack access to it

Drug for rare kidney disease narrowly misses mark in clinical trial

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Moonlake's readout produced a cash windfall. Risks remain

Chemotherapy drug shortage eases slightly but still widespread

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Lasker Awards 2023: Winners in biomedical research

leisure time

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Senate panel eyes new effort on drug shortages

3 questions for the future of Biden's cancer moonshot

A virus, fished out of a lake, may have saved a man’s life

Emergency workers more likely to restrain Black patients: study

Microbiome research is starting to find links to chronic diseases

Wikipedia

leisure time

entertainment

leisure time